In ALS Study, Essential Protein Seen as Promising New Theurapeutic Target
Researchers have identified an essential protein, Pur-alpha, for motor neuron cells’ mechanisms of defense against external stress and degeneration and also…
Articles by Margarida Azevedo, MSc
Key Players in Neuroinflammation Tied to ALS, Depression Highlighted
A recent review summarized the effects of immune system dysregulation and neuroinflammation in the regulation of critical pathways associated with depression and…
ALS, Other Muscle Diseases Focus of Company‘s Push to Expand Drug Candidates
Cytokinetics Inc. has presented its Vision 2020: Empowering Our Future – an initiative designed to expand the company’s…
ALS Protein Dynamics May Hold Clues for Disease Progression
Researchers at the National University of Singapore have suggested there is a fine balance between amyotrophic lateral sclerosis (ALS)-related protein TDP-43’s…
ALS Symptoms Found in Mice Lacking a Specific MicroRNA Molecule
Researchers at the Salk Institute have discovered that a set of messenger RNAs, controlled by the microRNA miR-218, define a…
Phi Delta Theta Fraternity Awards $100,000 to Milton Safenowitz Postdoctoral Research Fellow Studying ALS
The ALS Association has announced the Phi Delta Theta Fraternity is contributing to support the Milton Safenowitz Postdoctoral Fellow Program by…
Protein Clumps Linked to ALS Motor Neuron Death Seen for First Time
Researchers at University Of North Carolina School Of Medicine are reporting the first evidence-based description of the neuronal protein clumps thought to be toxic…
Isis Pharma’s ALS Candidate Drug Enters Clinical Trial
ISIS Pharmaceuticals, in collaboration with Biogen, has started a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067), one of the drug candidates…
Top 10 ALS News Stories of 2015
ALS News Today has published daily coverage of ALS-related advocacy events, clinical trials, and research throughout the year. As 2015 finally…
Ibudilast Granted FDA’s Fast Track Designation for ALS Treatment
MediciNova, Inc. announced its experimental therapy MN-166 (ibudilast) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for…